Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 27;12(10):1595.
doi: 10.3390/jpm12101595.

Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial

Elise Bonnet  1 , Véronique Haddad  2 , Stanislas Quesada  1   3 , Kim-Arthur Baffert  1   4 , Audrey Lardy-Cléaud  5 , Isabelle Treilleux  2 , Daniel Pissaloux  2   6   7 , Valéry Attignon  2 , Qing Wang  2 , Adrien Buisson  2 , Pierre-Etienne Heudel  1 , Thomas Bachelot  1 , Armelle Dufresne  1 , Lauriane Eberst  8 , Philippe Toussaint  1 , Valérie Bonadona  9   10 , Christine Lasset  9   10 , Alain Viari  11 , Emilie Sohier  11 , Sandrine Paindavoine  2 , Valérie Combaret  2 , David Pérol  5 , Isabelle Ray-Coquard  1   12   13 , Jean-Yves Blay  1   12   13 , Olivier Trédan  1   10
Affiliations

Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial

Elise Bonnet et al. J Pers Med. .

Abstract

Background: a specific subset of metastatic triple-negative breast cancers (mTNBC) is characterized by homologous recombination deficiency (HRD), leading to enhanced sensitivity to platinum-based chemotherapy. Apart from mutations in BRCA1/2 genes, the evaluation of other HRD-related alterations has been limited to date. As such, we analyzed data from mTNBC patients enrolled in the ProfiLER-01 study to determine the prevalence of alterations in homologous recombination-related (HRR) genes and their association with platinum sensitivity.

Methods: next-generation sequencing and promoter methylation of BRCA1 and RAD51C were performed on tumors from patients with mTNBC, using a panel of 19 HRR genes. Tumors were separated into three groups based on their molecular status: mutations in BRCA1/2, mutations in other HRR genes (BRCA1/2 excluded) or BRCA1/RAD51C promoter methylation and the absence of molecular alterations in HRR genes (groups A, B and C, respectively). Sensitivity to platinum-based chemotherapy was evaluated through the radiological response.

Results: mutations in BRCA1/2 were detected in seven (13.5%) patients, while alterations in other HRR genes or hypermethylation in BRCA1 or RAD51C were reported in 16 (30.7%) patients; furthermore, no alteration was found in the majority of patients (n = 29; 55.8%). Among 27 patients who received platinum-based chemotherapy, the disease control rate was 80%, 55% and 18% (groups A, B and C, respectively; p = 0.049). Regarding group B, patients with disease control exhibited mutations in FANCL, FANCA and the RAD51D genes or RAD51C methylation; Conclusion: mutations in HRR genes and epimutations in RAD51C were associated with disease control through platinum-based chemotherapy. As such, apart from well-characterized alterations in BRCA1/2, a more comprehensive evaluation of HRD should be considered in order to enlarge the selection of patients with mTNBC that could benefit from platinum-based chemotherapy.

Keywords: BRCA; DNA repair; HRR genes; TNBC; homologous recombination; platinum-based chemotherapy; triple-negative breast cancer.

PubMed Disclaimer

Conflict of interest statement

J.-Y.B.: received research support and honoraria from Astrazeneca, GSK, Novartis; P.-E.H. received grants and non-financial support from AstraZeneca, Roche, Novartis, Pfizer, personal fees from Mylan, personal fees and non-financial support from EISAI, outside the submitted work; I.R.-C.: received honoraria from AstraZeneca, Clovis, Tesaro and PharmaMar; Consulting/advisory board fees from AstraZeneca, Roche, Clovis, Tesaro, Genmab, PharmaMar, MSD and Pfizer, research funding from MSD and BMS, travel expenses from AstraZeneca, GSK and Roche; O.T.: received grants from Roche, MSD-Merck, BMS; personal fees from Roche, MSD-Merck, Novartis-Sandoz, Pfizer, Lilly, Astra-Zeneca, Daiichi Sankyo, Eisai, Pierre Fabre; D.P. (David Pérol): received honoraria from Astrazeneca, BMS, ELI-Lilly, IPSEN, Roche, Novartis, Pierre Fabre, MSD and Takeda, research funding from MSD Avenir, travel expenses from Astrazeneca; T.B.: received grants, advisory board fees and non-financial support from Novartis, AstraZeneca and Pfizer, advisory board fees and non-financial support from Roche, advisory board fees from SeattleGenetics. E.B., V.H., S.Q., K.-A.B., A.L.-C., Q.W., L.E., L.C., V.B., I.T., V.A., V.C., C.L., A.D., E.S., D.P. (Daniel Pissaloux), A.V., S.P., A.B. and P.T. declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Response to platinum-based therapy according to molecular status phenotype. Responses are given for each group taken separately (a), or by comparing patients with or without molecular alteration (groups A + B versus group C respectively) (b). * represents differences with statistical significance (p < 0.05).
Figure 2
Figure 2
Progression-free (a) and overall (b) survivals of patients challenged with platinum-based chemotherapy, according to molecular status.
Figure 3
Figure 3
Site of biopsy, molecular status and radiological response for each patient challenged with platinum-based chemotherapy. A black square indicates the presence of a given molecular alteration.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Bianchini G., De Angelis C., Licata L., Gianni L. Treatment Landscape of Triple-Negative Breast Cancer—Expanded Options, Evolving Needs. Nat. Rev. Clin. Oncol. 2022;19:91–113. doi: 10.1038/s41571-021-00565-2. - DOI - PubMed
    1. Zagami P., Carey L.A. Triple Negative Breast Cancer: Pitfalls and Progress. NPJ Breast Cancer. 2022;8:95. doi: 10.1038/s41523-022-00468-0. - DOI - PMC - PubMed
    1. Mahtani R., Kittaneh M., Kalinsky K., Mamounas E., Badve S., Vogel C., Lower E., Schwartzberg L., Pegram M., Breast Cancer Therapy Expert Group (BCTEG) Advances in Therapeutic Approaches for Triple-Negative Breast Cancer. Clin. Breast Cancer. 2021;21:383–390. doi: 10.1016/j.clbc.2020.12.011. - DOI - PubMed
    1. Belli C., Duso B.A., Ferraro E., Curigliano G. Homologous Recombination Deficiency in Triple Negative Breast Cancer. Breast. 2019;45:15–21. doi: 10.1016/j.breast.2019.02.007. - DOI - PubMed